|
|
|
|
|
½ÃÀ庸°í¼
Drug Discovery ºÎ¹®¿¡¼ GPCRÀÇ Àå·¡ : »õ·Î¿î Å×Å©³î·¯Áö, Áß¿ä±â¾÷, Ç¥ÀûÈ®´ë ±âȸ
The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
| ¸®¼Ä¡»ç |
Business Insights |
| ¹ßÇàÀÏ |
2010³â 04¿ù |
»óǰÄÚµå |
121619 |
| ÆäÀÌÁö Á¤º¸ |
Pages: 130 |
| °¡°Ý |
|
|
Business Insights ¿¡¼ 2010³â 04¿ù ¿¡ ¹ßÇàÇÑ ¡¸Drug Discovery ºÎ¹®¿¡¼ GPCRÀÇ Àå·¡ : »õ·Î¿î Å×Å©³î·¯Áö, Áß¿ä±â¾÷, Ç¥ÀûÈ®´ë ±âȸ¡¹ º¸°í¼´Â Pages: 130·Î ±¸¼ºµÇ¾î, US $3,835 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.
GPCR(G protein-coupled receptor,G´Ü¹éÁú ¿¬°á ¼ö¿ëü) ÀÇ °³¿ä¿Í â¾à±â¼ú·ÎÀÇ ÀÀ¿ë µ¿Çâ, ÀÌ ºÐ¾ßÀÇ Àü¹® ±â¾÷ °³¿ä¿Í ÇâÈÄ ½ÃÀå Àü¸Á µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. Á¦ 2 Àå GPCR (G´Ü¹éÁú ¿¬°á ¼ö¿ëü) ÀÇ Æ¯Â¡ - ¿ä¾à
- ¼·Ð
- ´Ü¹éÁú ±¸Á¶
- ±â´ÉÀû ¼ö¿ëü
Á¦ 3 Àå »ó¾÷Àû ÀÌ¿ë - ¿ä¾à
- ¼·Ð
- ÇöÀçÀÇ ¼º°ø
- Ÿ°ÙÀÌ µÇ´Â GPCR
- ¹Ì°³¹ßµÈ Ç¥Àû
- ¾î·Á¿î Ç¥Àû
- ±âȸ
Á¦ 4 Àå »õ·Î¿î Á¢±Ù - ¿ä¾à
- ¼·Ð
- ½ºÅ©¸®´× ¹æ¹ý(Screening methods)
- ±¸Á¶±â¹Ý ¹æ¹ý(Structure-based methods)
- Áö½Ä±â¹Ý ¹æ¹ý(Knowledge-based methods)
- ¾Ë·Î½ºÅ׸¯ Á¶ÀýÀÎÀÚ(Allosteric modulators)
- À̱â´É¼º ¸®°£µå(Bifunctional ligands)
- ÀÌ·®Ã¼¼ö¿ëüǥÀû¸®°£µå(Dimeric receptor targeting ligands)
- Biased ¸®°£µå
Á¦ 5 Àå »õ·Î¿î ±âȸ - ¿ä¾à
- ¼·Ð
- ¼±ÅüºÀÇ Çâ»ó
- »õ·Î¿î Ç¥Àû
- »õ·Î¿î ÀûÀº
Á¦ 6 Àå ±â¾÷ °³¿ä - ¿ä¾à
- ¼·Ð
- 7TM Pharma
- Actelion
- Acure Pharma
- Addex Pharmaceuticals
- Arena Pharmaceuticals
- Ascent Therapeutics
- Cara Therapeutics
- Compugen
- Dimerix Bioscience
- DiscoveRx
- Domain Therapeutics
- Euroscreen
- Galapagos
- Heptahelix
- Heptares Therapeutics
- Oxagen
- Prosarix
- Tranzyme Pharma
- Trevena
Á¦ 7 Àå ¾àÁ¦Ç¥Àû GPCR ½ÃÀåÀÇ ÇâÈÄ Àü¸Á - ¿ä¾à
- Áö¼ÓµÇ´Â ±âȸ
- ÇöÀç Ä¡·á¹ý
- ÇâÈÄ °³¹ßµÉ Ä¡·á¹ý
- ÀüüÀû Æò°¡
cyj
|

|